Companion Diagnostics Market by Product (Assays, Kits, & Reagents, Instruments, Software), Technology (PCR, NGS, ISH, IHC), Indication (Breast, Lung, Colorectal Cancer, CVD, Infectious), Drug Class (MAB, Cell & Gene Therapy) - Global Forecast to 2031

icon1
USD 11.57 BN
MARKET SIZE, 2031
icon2
CAGR 12.9%
(2026-2031)
icon3
500
REPORT PAGES
icon4
560
MARKET TABLES

OVERVIEW

companion-diagnostics-market Overview

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

The companion diagnostics market is projected to reach USD 11.57 billion by 2031, from USD 6.31 billion in 2026, with a CAGR of 12.9%. The market is driven by the rapid adoption of precision medicine, targeted therapies, and biomarker-based treatment approaches. Companion diagnostics (CDx) are essential for identifying patient populations most likely to benefit from specific therapies, particularly in oncology, autoimmune diseases, and rare genetic disorders. The market encompasses diagnostic assays, next-generation sequencing (NGS), PCR-based testing, immunohistochemistry, in situ hybridization, liquid biopsy technologies, bioinformatics platforms, and associated analytical services. Increasing regulatory emphasis on personalized therapeutics, growing pharma-diagnostic partnerships, and expanding approvals of targeted drugs are accelerating market growth globally.

KEY TAKEAWAYS

  • BY REGION
    North America accounted for the largest share of 44.7% in 2025.
  • BY PRODUCT & SERVICE
    The assays, kits & reagents segment captured 67.3% of the total market in 2025.
  • BY END USER
    Pharmaceutical & biotechnology companies dominated the companion diagnostics market in 2025.
  • COMPETITIVE LANDSCAPE - Key Players
    F. Hoffmann-La Roche AG (Switzerland), Agilent Technologies, Inc. (US), QIAGEN (Netherlands), and Thermo Fisher Scientific Inc. (US) were identified as stars in the companion diagnostics market, given their strong market share and product and service footprint.
  • COMPETITIVE LANDSCAPE - Startups
    Pillar Biosciences (US) and Biocartis (Belgium) have distinguished themselves among startups and SMEs by securing strong footholds in specialized niche areas, underscoring their potential as emerging market leaders.

The companion diagnostics market is expanding rapidly, driven by the increasing adoption of precision medicine, rising approvals of targeted therapies, and growing integration of biomarker-based testing into clinical decision-making. Advances in molecular diagnostics, NGS, liquid biopsy, and AI-enabled biomarker discovery are accelerating the adoption of companion diagnostics across drug development, oncology research, and personalized treatment applications.

TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS

The companion diagnostics market is rapidly transforming, driven by advances in precision medicine, NGS, liquid biopsy, and AI-enabled biomarker discovery platforms. The growing integration of companion diagnostics into targeted drug development and clinical trial stratification is accelerating demand for highly accurate, personalized diagnostic solutions across oncology and rare disease applications. The rising adoption of liquid biopsy and minimally invasive testing is disrupting traditional tissue-based diagnostic workflows by enabling real-time disease monitoring, therapy response assessment, and early mutation detection. In parallel, advances in digital pathology, multiplex biomarker analysis, cloud-based bioinformatics, and AI-driven clinical interpretation are improving diagnostic precision, turnaround time, and treatment decision support. Strategic collaborations between pharmaceutical companies and molecular diagnostics developers, along with evolving regulatory frameworks that support co-development of drugs and companion diagnostics, are strengthening commercialization opportunities. The expanding use of companion diagnostics beyond oncology into cardiovascular, autoimmune, and infectious diseases is further broadening market potential across hospitals, reference laboratories, CROs/CDMOs, and precision medicine research centers.

companion-diagnostics-market Disruptions

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

MARKET DYNAMICS

Drivers
Impact
Level
  • Increasing adoption of precision medicine and targeted therapies
  • Growing investments in genomics, molecular diagnostics, and biomarker discovery
RESTRAINTS
Impact
Level
  • High development, clinical validation, and regulatory approval costs
OPPORTUNITIES
Impact
Level
  • Expansion of liquid biopsy and non-invasive companion diagnostics
  • AI-driven biomarker interpretation and digital pathology integration
CHALLENGES
Impact
Level
  • Regulatory complexity associated with simultaneous drug–diagnostic approvals

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

Driver: Increasing adoption of precision medicine and targeted therapies

The growing focus on precision medicine is significantly driving demand for companion diagnostics, as healthcare providers increasingly rely on biomarker-based testing to personalize treatment decisions. The rising approvals of targeted therapies, particularly in oncology, are accelerating the integration of companion diagnostics into clinical workflows. Pharmaceutical companies are increasingly partnering with diagnostic developers to improve patient stratification and treatment efficacy.

Restraint: High development, clinical validation, and regulatory approval costs

Developing companion diagnostics requires substantial investment in biomarker discovery, assay development, clinical validation, and regulatory compliance. Simultaneous approval requirements for therapeutics and diagnostics increase development complexity and extend commercialization timelines. Smaller diagnostic companies often face financial and operational challenges in conducting large-scale validation studies. Reimbursement policy variability and limited coverage for molecular testing in certain regions further restrict market penetration. In addition, evolving global regulatory standards create additional compliance burdens for market participants.

Opportunity: Expansion of liquid biopsy and non-invasive companion diagnostics

The growing adoption of liquid biopsy technologies presents significant growth opportunities for the companion diagnostics market by enabling minimally invasive cancer detection and treatment monitoring. Liquid biopsy-based companion diagnostics improve patient convenience and support real-time assessment of tumor mutations and treatment response. Advancements in circulating tumor DNA (ctDNA), multi-cancer early detection, and AI-driven biomarker analysis are expanding the scope of precision diagnostics. Growing demand for decentralized and rapid testing solutions is further driving innovation in non-invasive diagnostic platforms. Expanding applications beyond oncology into rare and infectious diseases also offer long-term market potential.

Challenge: Regulatory complexity associated with simultaneous drug–diagnostic approvals

Companion diagnostics face significant regulatory challenges because both the therapeutic product and the associated diagnostic test must be approved in coordination. Differences in regulatory frameworks across regions complicate global commercialization strategies. Delays in aligning clinical trials, validating biomarkers, and submitting regulatory applications can affect product launch timelines and increase overall development costs. Ensuring analytical accuracy, reproducibility, and clinical utility across diverse patient populations remains a major challenge for diagnostic developers. Furthermore, evolving regulatory expectations regarding AI-enabled diagnostics and real-world evidence are adding additional layers of compliance complexity.

COMPANION DIAGNOSTICS MARKET SIZE, GROWTH, SHARE & TRENDS ANALYSIS: COMMERCIAL USE CASES ACROSS INDUSTRIES

COMPANY USE CASE DESCRIPTION BENEFITS
Develops companion diagnostics linked with targeted oncology therapies using PCR, IHC, and NGS platforms to identify biomarker-positive patient populations for therapies such as HER2, EGFR, and PD-L1 targeted treatments. Enables accurate patient stratification, improves therapy response rates, and supports faster clinical decision-making in precision oncology.
Provides companion diagnostic assays through Dako pathology platforms, including PD-L1 and immunohistochemistry-based biomarker testing for immuno-oncology applications. Improves biomarker detection consistency, supports immunotherapy adoption, and enhances pathology workflow standardization.
Provides therascreen companion diagnostic assays for detecting specific gene mutations across cancer indications, supporting therapy selection for targeted drugs in lung, colorectal, and breast cancers. Enhances treatment selection accuracy, reduces ineffective therapies, and supports regulatory-approved personalized treatment pathways.

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

MARKET ECOSYSTEM

The companion diagnostics market is a highly interconnected precision medicine ecosystem in which pharmaceutical and biopharmaceutical companies, diagnostic assay developers, sequencing and pathology platform providers, reference laboratories, hospitals, oncology centers, academic institutions, and regulatory bodies collaborate to enable biomarker-driven treatment decisions. Pharmaceutical companies work closely with in vitro diagnostic manufacturers and specialized molecular diagnostics firms to co-develop and commercialize companion diagnostic tests alongside targeted therapies, immunotherapies, and emerging cell and gene therapies. Diagnostic ecosystem participants provide assays, kits, reagents, instruments, sequencing platforms, IHC/ISH systems, bioinformatics tools, and interpretation software to identify actionable biomarkers such as EGFR, ALK, HER2, KRAS, BRAF, BRCA, PD-L1, MSI/MMR, NTRK, RET, and MET. Reference laboratories, hospital molecular pathology labs, and cancer centers support clinical implementation by performing CDx testing, reporting actionable results, and integrating biomarker data into oncology treatment pathways. CROs and specialized clinical research service providers support biomarker discovery, assay validation, clinical trial patient selection, regulatory submissions, and post-commercialization testing strategies. Regulatory authorities such as the US FDA, EMA, PMDA, and other national agencies, along with payers and health technology assessment bodies, shape the ecosystem through approval pathways, clinical utility requirements, reimbursement policies, and companion diagnostic labeling standards.

companion-diagnostics-market Ecosystem

Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.

MARKET SEGMENTS

companion-diagnostics-market Segments

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

Global Companion Diagnostics Market, by Product & Service

Assays, kits & reagents are expected to account for the largest share of the companion diagnostics market due to their recurring use across PCR, NGS, IHC, and ISH-based testing workflows. These consumables are required for every patient test, unlike instruments, which are capital purchases with longer replacement cycles. Growing biomarker testing volumes in oncology, especially for lung, breast, and colorectal cancers and hematologic malignancies, continue to support demand for CDx assay kits and reagents.

Global Companion Diagnostics Market, by Technology

PCR is expected to hold the largest share of the companion diagnostics market due to its wide clinical use, faster turnaround time, lower cost, and strong adoption across targeted mutation testing workflows. PCR-based CDx assays are widely used for actionable biomarkers such as EGFR, KRAS/NRAS, BRAF, BRCA mutations, MSI-related testing, and selected infectious or oncology-linked molecular targets.

Global Companion Diagnostics Market, by Indication

Cancer is expected to dominate the companion diagnostics market, accounting for the vast majority of demand. Within cancer, lung cancer is likely to hold the largest share, driven by a high number of actionable biomarkers, including EGFR, ALK, ROS1, BRAF, MET, RET, NTRK, KRAS, and PD-L1, as well as broader NGS-based profiling. Breast cancer and colorectal cancer also represent major CDx indications, supported by HER2, ER/PR, BRCA/HRD, RAS, BRAF, and MSI/MMR testing.

Global Companion Diagnostics Market, by Sample

Tissue samples are expected to hold the largest share of the companion diagnostics market because most approved and reimbursed CDx workflows remain tissue-based. Tissue testing is central to IHC, ISH/FISH, and many NGS assays used in solid tumors, especially for HER2, PD-L1, ALK, MMR, and comprehensive tumor profiling.

Global Companion Diagnostics Market, by End User

Pharmaceutical & biopharmaceutical companies are expected to account for the largest share of the companion diagnostics market because of their central role in CDx co-development, clinical trial patient selection, regulatory submissions, and the commercialization of targeted therapies. These companies drive demand for companion diagnostic assays throughout drug development and post-approval use, particularly across oncology, immunotherapy, and precision medicine pipelines.

REGION

Asia Pacific to be fastest-growing region during forecast period

During the forecast period, Asia Pacific is expected to be the fastest-growing region in the companion diagnostics market, driven by rising cancer incidence, expanding adoption of precision oncology, increasing use of PCR- and NGS-based biomarker testing, and improving access to targeted therapies across China, Japan, South Korea, Australia, and India. Japan and South Korea are advancing reimbursement and clinical adoption of comprehensive genomic profiling, while China and India are witnessing rapid expansion of molecular diagnostics infrastructure, oncology reference laboratories, and pharma-led biomarker testing programs. Growing clinical trial activity, increasing approvals of targeted therapies, and broader use of liquid biopsy and multi-gene testing are expected to further support regional growth. However, adoption will remain uneven across the region due to differences in reimbursement maturity, testing affordability, and access to advanced oncology care.

companion-diagnostics-market Region

COMPANION DIAGNOSTICS MARKET SIZE, GROWTH, SHARE & TRENDS ANALYSIS: COMPANY EVALUATION MATRIX

F. Hoffmann-La Roche AG is a leading player in the companion diagnostics market, supported by its broad portfolio spanning tissue diagnostics, immunohistochemistry, in situ hybridization, PCR-based testing, and comprehensive genomic profiling through Foundation Medicine. The company has strong pharmaceutical linkages, regulatory experience, and a wide installed base across pathology and oncology testing workflows, positioning it well in therapy-linked biomarker testing. Guardant Health and Tempus are emerging high-growth players, supported by liquid biopsy, AI-enabled molecular profiling, and the extensive use of NGS-based companion diagnostics in advanced oncology.

companion-diagnostics-market Evaluation Metrics

Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis

KEY MARKET PLAYERS

MARKET SCOPE

REPORT METRIC DETAILS
Market Size in 2025 (Value) USD 5.66 BN
Market Forecast in 2031 (Value) USD 11.57 BN
Growth Rate CAGR of 12.9 from 2026 to 2031
Years Considered 2024–2031
Base Year 2025
Forecast Period 2026–2031
Units Considered Value (USD BN/MN)
Report Coverage Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Segments Covered
  • By Product & Services:
    • Assays
    • Kits & Reagents
    • Instruments/Systems
    • Software & Services
  • By Technology:
    • Polymerase Chain Reaction
    • Next Generation Sequencing
    • In Situ Hybridization
    • Immunohistochemistry
    • Other Technologies
  • By Indication:
    • Cancer
    • Infectious Diseases
    • Cardiovascular Diseases
    • Neurological Diseases
    • Other Indications
  • By Sample:
    • Tissue
    • Blood
    • Other Samples
  • By Drug Class Associated with CDx:
    • Monoclonal Antibodies
    • Cell & Gene Therapy
  • By Application:
    • Clinical Diagnostics
    • Research Use
  • By End User:
    • Pharmaceutical & Biotechnology Companies
    • Reference Laboratories
    • CROs
    • Academic & Research Institutes
    • Other End Users
  •  
Regions Covered North America, Europe, Asia Pacific, Latin America, Middle East, Africa

WHAT IS IN IT FOR YOU: COMPANION DIAGNOSTICS MARKET SIZE, GROWTH, SHARE & TRENDS ANALYSIS REPORT CONTENT GUIDE

companion-diagnostics-market Content Guide

DELIVERED CUSTOMIZATIONS

We have successfully delivered the following deep-dive customizations:

CLIENT REQUEST CUSTOMIZATION DELIVERED VALUE ADDS
Evaluate competitive positioning of key players in the companion diagnostics market Benchmarked leading companies across CDx assays, kits, reagents, instruments/systems, NGS platforms, IHC/ISH solutions, liquid biopsy tests, bioinformatics, and reference laboratory services based on technology coverage, approved CDx portfolio, pharma partnerships, geographic reach, regulatory approvals, and end-user focus. Identifies competitive gaps, partnership opportunities, and differentiation strategies
Assess high-growth technologies and segment opportunities in companion diagnostics Evaluated growth potential across PCR, NGS, IHC, ISH/FISH, liquid biopsy, tissue-based testing, blood-based testing, and software-enabled interpretation workflows, including differences in adoption across oncology, infectious disease, cardiovascular, neurological, and other indications Supports investment prioritization, product development, CDx co-development planning, regional expansion, and technology roadmap decisions, especially around NGS, liquid biopsy, and biomarker-driven oncology testing

RECENT DEVELOPMENTS

  • May 2026 : F. Hoffmann-La Roche AG agreed to acquire PathAI to strengthen its digital pathology and AI-enabled precision diagnostics capabilities. The deal builds on Roche and PathAI’s earlier collaboration, which expanded in 2024 to include AI-enabled companion diagnostic algorithm development, supporting Roche’s position in tissue-based oncology diagnostics and biomarker interpretation
  • December 2025 : The FDA approved AstraZeneca and Daiichi Sankyo’s Enhertu in combination with F. Hoffmann-La Roche AG's Perjeta for first-line treatment of HER2-positive metastatic breast cancer, with the approval linked to FDA-approved companion diagnostic testing for HER2-positive patient identification. This reinforces the continued importance of HER2 testing in therapy selection.

Table of Contents

Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.

TITLE
PAGE NO
INTRODUCTION
30
RESEARCH METHODOLOGY
36
EXECUTIVE SUMMARY
50
PREMIUM INSIGHTS
55
MARKET OVERVIEW
59
  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    DRIVERS
    - Ability of CDx tests to reduce healthcare costs and increase efficiency
    - Growing focus on targeted therapy
    - Rising demand for personalized medicine
    - Increasing incidence of cancer and subsequent adoption of CDx-based oncology medicine
    - Growing application areas for companion diagnostics
    RESTRAINTS
    - Significant capital investment and low cost-benefit ratio
    - High cost of companion diagnostic tests
    - Unfavorable reimbursements
    - High cost of immunotherapy treatment
    OPPORTUNITIES
    - Increasing demand for next-generation sequencing
    - Growing significance of companion diagnostics in drug development
    - Advancements in genomics research and rising clinical trials
    CHALLENGES
    - Shortage of healthcare professionals
    - Limited awareness in emerging markets
  • 5.3 PRICING ANALYSIS
  • 5.4 PATENT ANALYSIS
  • 5.5 TRADE ANALYSIS
    TRADE ANALYSIS FOR DIAGNOSTIC & LABORATORY REAGENTS
  • 5.6 VALUE CHAIN ANALYSIS
  • 5.7 SUPPLY CHAIN ANALYSIS
  • 5.8 ECOSYSTEM ANALYSIS
  • 5.9 PORTER’S FIVE FORCES ANALYSIS
    THREAT OF NEW ENTRANTS
    THREAT OF SUBSTITUTES
    BARGAINING POWER OF BUYERS
    BARGAINING POWER OF SUPPLIERS
    INTENSITY OF COMPETITIVE RIVALRY
  • 5.10 REGULATORY LANDSCAPE
    REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    NORTH AMERICA
    - US
    - Canada
    EUROPE
    ASIA PACIFIC
    - China
    - Japan
    - India
    LATIN AMERICA
    - Brazil
    - Mexico
    MIDDLE EAST
    AFRICA
  • 5.11 TECHNOLOGY ANALYSIS
    KEY TECHNOLOGIES
    - Polymerase chain reaction (PCR)
    - Next-generation sequencing (NGS)
    COMPLIMENTARY TECHNOLOGIES
    - In situ hybridization (ISH)
    ADJACENT TECHNOLOGIES
    - Immunohistochemistry (IHC)
  • 5.12 KEY CONFERENCES & EVENTS IN 2024–2025
  • 5.13 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
    REVENUE POCKETS FOR COMPANION DIAGNOSTICS MARKET
  • 5.14 KEY STAKEHOLDERS & BUYING CRITERIA
    KEY STAKEHOLDERS IN BUYING PROCESS
    BUYING CRITERIA
  • 5.15 INVESTMENT AND FUNDING SCENARIO
COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE
88
  • 6.1 INTRODUCTION
  • 6.2 ASSAYS, KITS, AND REAGENTS
    INCREASING VOLUME OF CDX TESTS IN LABORATORIES TO SUPPORT ADOPTION OF ASSAYS & KITS
  • 6.3 INSTRUMENTS & SYSTEMS
    LATEST ADVANCEMENTS IN NGS TECHNOLOGIES TO ENSURE MARKET GROWTH
  • 6.4 SOFTWARE & SERVICES
    NEED TO DELIVER ACCURATE AND TIMELY ANALYSIS OF DIAGNOSTICS TESTS TO SUPPORT MARKET GROWTH
COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY
100
  • 7.1 INTRODUCTION
  • 7.2 POLYMERASE CHAIN REACTION
    GROWING APPLICATIONS IN PERSONALIZED MEDICINE AND COMPANION DIAGNOSTICS TO DRIVE GROWTH
  • 7.3 IN SITU HYBRIDIZATION
    INCREASING DEMAND IN SMALL TUMOR DIAGNOSTICS TO DRIVE GROWTH
  • 7.4 NEXT-GENERATION SEQUENCING
    ADVANTAGES SUCH AS ACCURACY, SENSITIVITY, AND SPEED TO SUPPORT MARKET GROWTH
  • 7.5 IMMUNOHISTOCHEMISTRY
    INCREASING DEMAND FOR USER-FRIENDLY AND COST-EFFECTIVE TECHNOLOGIES TO SUPPORT GROWTH
  • 7.6 OTHER TECHNOLOGIES
COMPANION DIAGNOSTICS MARKET, BY INDICATION
119
  • 8.1 INTRODUCTION
  • 8.2 CANCER
    LUNG CANCER
    - Growing demand for effective therapeutic drugs to increase CDx adoption
    BREAST CANCER
    - Wide prevalence of breast cancer to boost market growth
    BLOOD CANCER
    - Growing incidence of blood cancer to drive market
    COLORECTAL CANCER
    - Rising need for molecular profiling of primary tumors to drive segment growth
    OTHER CANCERS
  • 8.3 NEUROLOGICAL DISEASES
    GROWING NUMBER OF ADVANCED TECHNOLOGIES TO BOOST ADOPTION OF COMPANION DIAGNOSTICS
  • 8.4 CARDIOVASCULAR DISEASES
    INCREASING DEMAND FOR TARGETED THERAPIES TO DRIVE SEGMENT GROWTH
  • 8.5 INFECTIOUS DISEASES
    INCREASING AWARENESS OF TARGETED THERAPIES TO PROPEL GROWTH
  • 8.6 OTHER INDICATIONS
COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE
150
  • 9.1 INTRODUCTION
  • 9.2 TISSUE SAMPLES
    COMPREHENSIVE PROFILING AND HIGH SENSITIVITY TO DRIVE MARKET
  • 9.3 BLOOD SAMPLES
    LESS INVASIVE METHOD—KEY FACTOR DRIVING ADOPTION
  • 9.4 OTHER SAMPLE TYPES
COMPANION DIAGNOSTICS MARKET, BY END USER
161
  • 10.1 INTRODUCTION
  • 10.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
    RISING DEMAND FOR PERSONALIZED MEDICINE TO DRIVE MARKET
  • 10.3 REFERENCE LABORATORIES
    RISING DEMAND FOR TARGETED THERAPIES TO DRIVE GROWTH
  • 10.4 CONTRACT RESEARCH ORGANIZATIONS
    RISING DEMAND FOR COMPANION DIAGNOSTIC PRODUCTS FOR USE IN THERAPY-RELATED CLINICAL TRIALS TO PROPEL GROWTH
  • 10.5 OTHER END USERS
COMPANION DIAGNOSTICS MARKET, BY REGION
175
  • 11.1 INTRODUCTION
  • 11.2 NORTH AMERICA
    NORTH AMERICA: RECESSION IMPACT
    US
    - Increasing use of companion diagnostics for cancer treatment to boost market growth
    CANADA
    - Increasing government initiatives to drive market
  • 11.3 EUROPE
    EUROPE: RECESSION IMPACT
    GERMANY
    - Increasing healthcare expenditure to drive market
    UK
    - Growing life science industry and increasing focus on research to propel market
    SWITZERLAND
    - Strong research-oriented pharma industry to support market growth
    FRANCE
    - Increasing government funding for research to support market growth
    ITALY
    - Growing geriatric population in region to drive market
    SPAIN
    - Increasing focus on advancement of personalized medicine to drive market growth
    REST OF EUROPE
  • 11.4 ASIA PACIFIC
    ASIA PACIFIC: RECESSION IMPACT
    CHINA
    - Advancements in healthcare facilities to drive market
    JAPAN
    - Increasing research initiatives to support market growth
    INDIA
    - Increased demand for early cancer diagnosis to fuel market growth
    AUSTRALIA
    - Initiatives to enhance healthcare access and infrastructure for aging population to drive market
    REST OF ASIA PACIFIC
  • 11.5 LATIN AMERICA
    LATIN AMERICA: RECESSION IMPACT
    BRAZIL
    - Increasing incidence of lifestyle diseases to favor market growth
    MEXICO
    - Growing medical tourism to fuel demand for companion diagnostics
    REST OF LATIN AMERICA
  • 11.6 MIDDLE EAST & AFRICA
    INCREASING FOCUS ON PRECISION MEDICINE TO DRIVE MARKET GROWTH
    MIDDLE EAST & AFRICA: RECESSION IMPACT
  • 11.7 GCC COUNTRIES
    GROWING HEALTHCARE INFRASTRUCTURE TO FUEL MARKET GROWTH
    GCC COUNTRIES: RECESSION IMPACT
COMPETITIVE LANDSCAPE
264
  • 12.1 INTRODUCTION
  • 12.2 RIGHT-TO-WIN APPROACHES ADOPTED BY KEY PLAYERS
  • 12.3 REVENUE SHARE ANALYSIS
  • 12.4 MARKET SHARE ANALYSIS
  • 12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS
    STARS
    EMERGING LEADERS
    PERVASIVE PLAYERS
    PARTICIPANTS
    COMPANY FOOTPRINT
    - Overall footprint
    - Product footprint
    - Technology footprint
    - Indication footprint
    - Regional footprint
  • 12.6 COMPETITIVE EVALUATION MATRIX: START-UPS/SMES
    PROGRESSIVE COMPANIES
    RESPONSIVE COMPANIES
    DYNAMIC COMPANIES
    STARTING BLOCKS
    COMPETITIVE BENCHMARKING
  • 12.7 VALUATION AND FINANCIAL METRICS OF COMPANION DIAGNOSTICS VENDORS
  • 12.8 BRAND/PRODUCT COMPARATIVE ANALYSIS
    F. HOFFMANN-LA ROCHE LTD.
    AGILENT TECHNOLOGIES, INC.
    QIAGEN
    THERMO FISHER SCIENTIFIC INC.
    ABBOTT
  • 12.9 COMPETITIVE SCENARIO
    PRODUCT LAUNCHES & APPROVALS
    DEALS
COMPANY PROFILES
279
  • 13.1 KEY PLAYERS
    F. HOFFMANN-LA ROCHE LTD.
    - Business overview
    - Products/Services/Solutions offered
    - Recent developments
    - MnM view
    AGILENT TECHNOLOGIES, INC.
    - Business overview
    - Products/Services/Solutions offered
    - Recent developments
    - MnM view
    QIAGEN
    - Business overview
    - Products/Services/Solutions offered
    - Recent developments
    - MnM view
    THERMO FISHER SCIENTIFIC INC.
    - Business overview
    - Products/Services/Solutions offered
    - Recent developments
    - MnM view
    ABBOTT
    - Business overview
    - Products/Services/Solutions offered
    - MnM view
    DANAHER
    - Business overview
    - Products/Services/Solutions offered
    GUARDANT HEALTH
    - Business overview
    - Products/Services/Solutions offered
    - Recent developments
    ILLUMINA, INC.
    - Business overview
    - Products/Services/Solutions offered
    - Recent developments
    BIOMÉRIEUX
    - Business overview
    - Products/Services/Solutions offered
    ICON PLC
    - Business overview
    - Products/Services/Solutions offered
    MYRIAD GENETICS, INC.
    - Business overview
    - Products/Services/Solutions offered
    - Recent developments
    SYSMEX CORPORATION
    - Business overview
    - Products/Services/Solutions offered
    - Recent developments
  • 13.2 OTHER PLAYERS
    ALMAC GROUP
    ARUP LABORATORIES
    ABNOVA CORPORATION
    BIOGENEX
    INVIVOSCRIBE, INC.
    ARCHERDX, INC.
    Q² SOLUTIONS
    AMOY DIAGNOSTICS CO., LTD.
    UNIOGEN
    ASURAGEN, INC.
    MESO SCALE DIAGNOSTICS, LLC
    CREATIVE BIOLABS
    NG BIOTECH
APPENDIX
340
  • 14.1 DISCUSSION GUIDE
  • 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
  • 14.3 CUSTOMIZATION OPTIONS
  • 14.4 RELATED REPORTS
  • 14.5 AUTHOR DETAILS
LIST OF TABLES
 
  • TABLE 1 ESTIMATED NUMBER OF NEW CANCER CASES FOR BOTH GENDERS (AGE: 0–85+), 2022 VS. 2045
  • TABLE 2 COMPANION DIAGNOSTICS MARKET: REIMBURSEMENT GUIDELINES ACROSS REGIONS
  • TABLE 3 DEALS UNDERTAKEN FOR DEVELOPMENT OF NGS-BASED COMPANION DIAGNOSTIC TESTS
  • TABLE 4 LIST OF FDA-APPROVED DRUGS WITH CDX ASSAYS
  • TABLE 5 INDICATIVE PRICING FOR COMPANION DIAGNOSTICS PRODUCTS
  • TABLE 6 AVERAGE SELLING PRICE OF COMPANION DIAGNOSTICS PRODUCTS, BY REGION
  • TABLE 7 IMPORT DATA FOR DIAGNOSTIC & LABORATORY REAGENTS, BY COUNTRY, 2018−2022 (USD MILLION)
  • TABLE 8 EXPORT DATA FOR DIAGNOSTIC & LABORATORY REAGENTS, BY COUNTRY, 2018−2022 (USD MILLION)
  • TABLE 9 COMPANION DIAGNOSTICS MARKET: ROLE IN ECOSYSTEM
  • TABLE 10 COMPANION DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS
  • TABLE 11 NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 12 ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 13 LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 14 REST OF THE WORLD: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 15 EUROPE: CLASSIFICATION OF DEVICES
  • TABLE 16 JAPAN: TIME, COST, AND COMPLEXITY OF REGISTRATION PROCESS
  • TABLE 17 COMPANION DIAGNOSTICS MARKET: DETAILED LIST OF CONFERENCES & EVENTS
  • TABLE 18 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR COMPANION DIAGNOSTICS PRODUCTS (%)
  • TABLE 19 KEY BUYING CRITERIA FOR COMPANION DIAGNOSTICS PRODUCTS
  • TABLE 20 COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
  • TABLE 21 ASSAYS & KITS: PRODUCTS OFFERED, BY COMPANY
  • TABLE 22 COMPANION DIAGNOSTICS MARKET FOR ASSAYS, KITS, AND REAGENTS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 23 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR ASSAYS, KITS, AND REAGENTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 24 EUROPE: COMPANION DIAGNOSTICS MARKET FOR ASSAYS, KITS, AND REAGENTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 25 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR ASSAYS, KITS, AND REAGENTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 26 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR ASSAYS, KITS, AND REAGENTS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 27 INSTRUMENTS & SYSTEMS: PRODUCTS OFFERED, BY COMPANY
  • TABLE 28 COMPANION DIAGNOSTICS MARKET FOR INSTRUMENTS & SYSTEMS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 29 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR INSTRUMENTS & SYSTEMS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 30 EUROPE: COMPANION DIAGNOSTICS MARKET FOR INSTRUMENTS & SYSTEMS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 31 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR INSTRUMENTS & SYSTEMS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 32 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR INSTRUMENTS & SYSTEMS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 33 SOFTWARE & SERVICES: PRODUCTS OFFERED, BY COMPANY
  • TABLE 34 COMPANION DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 35 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 36 EUROPE: COMPANION DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2022–2029 (USD MILLION
  • TABLE 37 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 38 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 39 COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 40 COMPARISON OF TISSUE SEQUENCING PLATFORMS FOR DETECTION OF RAS/BRAF MUTATION
  • TABLE 41 MAJOR PCR TESTS/KITS AVAILABLE
  • TABLE 42 COMPANION DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 43 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 44 EUROPE: COMPANION DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 45 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 46 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR POLYMERASE CHAIN REACTION, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 47 MAJOR ISH TESTS/KITS AVAILABLE
  • TABLE 48 COMPANION DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 49 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 50 EUROPE: COMPANION DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 51 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 52 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR IN SITU HYBRIDIZATION, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 53 MAJOR NGS TESTS/KITS AVAILABLE
  • TABLE 54 COMPANION DIAGNOSTICS MARKET FOR NEXT-GENERATION SEQUENCING, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 55 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 56 EUROPE: COMPANION DIAGNOSTICS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 57 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 58 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 59 MAJOR IHC TESTS/KITS AVAILABLE
  • TABLE 60 COMPANION DIAGNOSTICS MARKET FOR IMMUNOHISTOCHEMISTRY, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 61 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 62 EUROPE: COMPANION DIAGNOSTICS MARKET FOR IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 63 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 64 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 65 COMPANION DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 66 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 67 EUROPE: COMPANION DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 68 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 69 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR OTHER TECHNOLOGIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 70 COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD MILLION)
  • TABLE 71 ESTIMATED NUMBER OF CANCER CASES, BY REGION, 2022 VS. 2040
  • TABLE 72 COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 73 COMPANION DIAGNOSTICS MARKET FOR CANCER, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 74 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 75 EUROPE: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 76 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 77 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 78 ESTIMATED NUMBER OF LUNG CANCER CASES, BY REGION, 2022 VS. 2040
  • TABLE 79 COMPANION DIAGNOSTICS MARKET FOR LUNG CANCER, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 80 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR LUNG CANCER, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 81 EUROPE: COMPANION DIAGNOSTICS MARKET FOR LUNG CANCER, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 82 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR LUNG CANCER, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 83 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR LUNG CANCER, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 84 ESTIMATED NUMBER OF BREAST CANCER CASES, BY REGION, 2022 VS. 2040
  • TABLE 85 COMPANION DIAGNOSTICS MARKET FOR BREAST CANCER, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 86 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR BREAST CANCER, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 87 EUROPE: COMPANION DIAGNOSTICS MARKET FOR BREAST CANCER, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 88 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR BREAST CANCER, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 89 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR BREAST CANCER, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 90 ESTIMATED NUMBER OF LEUKEMIA CASES, BY REGION, 2022 VS. 2040
  • TABLE 91 COMPANION DIAGNOSTICS MARKET FOR BLOOD CANCER, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 92 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR BLOOD CANCER, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 93 EUROPE: COMPANION DIAGNOSTICS MARKET FOR BLOOD CANCER, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 94 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR BLOOD CANCER, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 95 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR BLOOD CANCER, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 96 ESTIMATED NUMBER OF COLORECTAL CANCER CASES, BY REGION, 2022 VS. 2040
  • TABLE 97 COMPANION DIAGNOSTICS MARKET FOR COLORECTAL CANCER, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 98 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 99 EUROPE: COMPANION DIAGNOSTICS MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 100 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 101 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR COLORECTAL CANCER, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 102 COMPANION DIAGNOSTICS MARKET FOR OTHER CANCERS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 103 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR OTHER CANCERS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 104 EUROPE: COMPANION DIAGNOSTICS MARKET FOR OTHER CANCERS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 105 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR OTHER CANCERS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 106 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR OTHER CANCERS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 107 COMPANION DIAGNOSTICS MARKET FOR NEUROLOGICAL DISEASES, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 108 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 109 EUROPE: COMPANION DIAGNOSTICS MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 110 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 111 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR NEUROLOGICAL DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 112 COMPANION DIAGNOSTICS MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 113 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 114 EUROPE: COMPANION DIAGNOSTICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 115 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 116 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 117 COMPANION DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 118 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 119 EUROPE: COMPANION DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 120 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 121 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 122 COMPANION DIAGNOSTICS MARKET FOR OTHER INDICATIONS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 123 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 124 EUROPE: COMPANION DIAGNOSTICS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 125 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 126 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 127 COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION)
  • TABLE 128 EXAMPLES OF FDA-APPROVED TISSUE-BASED COMPANION DIAGNOSTIC PRODUCTS
  • TABLE 129 COMPANION DIAGNOSTICS MARKET FOR TISSUE SAMPLES, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 130 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR TISSUE SAMPLES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 131 EUROPE: COMPANION DIAGNOSTICS MARKET FOR TISSUE SAMPLES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 132 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR TISSUE SAMPLES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 133 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR TISSUE SAMPLES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 134 EXAMPLES OF FDA-APPROVED BLOOD-BASED COMPANION DIAGNOSTIC PRODUCTS
  • TABLE 135 COMPANION DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 136 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 137 EUROPE: COMPANION DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 138 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 139 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR BLOOD SAMPLES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 140 EXAMPLES OF OTHER SAMPLE-BASED COMPANION DIAGNOSTIC PRODUCTS
  • TABLE 141 COMPANION DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 142 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 143 EUROPE: COMPANION DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 144 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 145 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR OTHER SAMPLE TYPES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 146 COMPANION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 147 COMPANION DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 148 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 149 EUROPE: COMPANION DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 150 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 151 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 152 COMPANION DIAGNOSTICS MARKET FOR REFERENCE LABORATORIES, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 153 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 154 EUROPE: COMPANION DIAGNOSTICS MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 155 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 156 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR REFERENCE LABORATORIES, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 157 COMPANION DIAGNOSTICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 158 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 159 EUROPE: COMPANION DIAGNOSTICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 160 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 161 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 162 COMPANION DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 163 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 164 EUROPE: COMPANION DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 165 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 166 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 167 COMPANION DIAGNOSTICS MARKET, BY REGION, 2022–2029 (USD MILLION)
  • TABLE 168 NUMBER OF NEW CANCER CASES IN NORTH AMERICA, BY TYPE OF CANCER, 2022 VS. 2045
  • TABLE 169 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 170 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
  • TABLE 171 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 172 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD MILLION)
  • TABLE 173 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 174 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION)
  • TABLE 175 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 176 US: CANCER INCIDENCE, BY TYPE OF CANCER, 2022 VS. 2040
  • TABLE 177 US: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
  • TABLE 178 US: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 179 US: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD MILLION)
  • TABLE 180 US: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 181 US: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION)
  • TABLE 182 US: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 183 CANADA: CANCER INCIDENCE, BY TYPE OF CANCER, 2022 VS. 2040
  • TABLE 184 CANADA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
  • TABLE 185 CANADA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 186 CANADA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD MILLION)
  • TABLE 187 CANADA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 188 CANADA: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION)
  • TABLE 189 CANADA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 190 EUROPE: COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 191 EUROPE: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
  • TABLE 192 EUROPE: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 193 EUROPE: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD MILLION)
  • TABLE 194 EUROPE: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 195 EUROPE: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION)
  • TABLE 196 EUROPE: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 197 GERMANY: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
  • TABLE 198 GERMANY: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 199 GERMANY: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD MILLION)
  • TABLE 200 GERMANY: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 201 GERMANY: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION)
  • TABLE 202 GERMANY: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 203 UK: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
  • TABLE 204 UK: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 205 UK: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD MILLION)
  • TABLE 206 UK: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 207 UK: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION)
  • TABLE 208 UK: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 209 SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
  • TABLE 210 SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 211 SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD MILLION)
  • TABLE 212 SWITZERLAND: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 213 SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION)
  • TABLE 214 SWITZERLAND: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 215 FRANCE: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
  • TABLE 216 FRANCE: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 217 FRANCE: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD MILLION)
  • TABLE 218 FRANCE: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 219 FRANCE: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION)
  • TABLE 220 FRANCE: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 221 ITALY: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
  • TABLE 222 ITALY: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 223 ITALY: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD MILLION)
  • TABLE 224 ITALY: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 225 ITALY: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION)
  • TABLE 226 ITALY: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 227 SPAIN: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
  • TABLE 228 SPAIN: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 229 SPAIN: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD MILLION)
  • TABLE 230 SPAIN: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 231 SPAIN: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION)
  • TABLE 232 SPAIN: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 233 REST OF EUROPE: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
  • TABLE 234 REST OF EUROPE: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 235 REST OF EUROPE: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD MILLION)
  • TABLE 236 REST OF EUROPE: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 237 REST OF EUROPE: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION)
  • TABLE 238 REST OF EUROPE: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 239 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 240 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
  • TABLE 241 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 242 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD MILLION)
  • TABLE 243 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 244 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION)
  • TABLE 245 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 246 CHINA: CANCER INCIDENCE, BY TYPE OF CANCER, 2022 VS. 2040
  • TABLE 247 CHINA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
  • TABLE 248 CHINA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 249 CHINA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD MILLION)
  • TABLE 250 CHINA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 251 CHINA: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION)
  • TABLE 252 CHINA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 253 JAPAN: CANCER INCIDENCE, BY TYPE OF CANCER, 2022 VS. 2040
  • TABLE 254 JAPAN: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
  • TABLE 255 JAPAN: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 256 JAPAN: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD MILLION)
  • TABLE 257 JAPAN: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 258 JAPAN: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION)
  • TABLE 259 JAPAN: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 260 INDIA: CANCER INCIDENCE, BY TYPE OF CANCER, 2022 VS. 2040
  • TABLE 261 INDIA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
  • TABLE 262 INDIA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 263 INDIA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD MILLION)
  • TABLE 264 INDIA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 265 INDIA: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION)
  • TABLE 266 INDIA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 267 AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
  • TABLE 268 AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 269 AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD MILLION)
  • TABLE 270 AUSTRALIA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 271 AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION)
  • TABLE 272 AUSTRALIA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 273 REST OF ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
  • TABLE 274 REST OF ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 275 REST OF ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD MILLION)
  • TABLE 276 REST OF ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 277 REST OF ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION)
  • TABLE 278 REST OF ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 279 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
  • TABLE 280 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
  • TABLE 281 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 282 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD MILLION)
  • TABLE 283 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 284 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION)
  • TABLE 285 LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 286 BRAZIL: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
  • TABLE 287 BRAZIL: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 288 BRAZIL: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD MILLION)
  • TABLE 289 BRAZIL: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 290 BRAZIL: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION)
  • TABLE 291 BRAZIL: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 292 MEXICO: NEW CANCER CASES, 2022
  • TABLE 293 MEXICO: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
  • TABLE 294 MEXICO: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 295 MEXICO: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD MILLION)
  • TABLE 296 MEXICO: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 297 MEXICO: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION)
  • TABLE 298 MEXICO: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 299 REST OF LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
  • TABLE 300 REST OF LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 301 REST OF LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD MILLION)
  • TABLE 302 REST OF LATIN AMERICA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 303 REST OF LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION)
  • TABLE 304 REST OF LATIN AMERICA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 305 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
  • TABLE 306 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 307 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD MILLION)
  • TABLE 308 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 309 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION)
  • TABLE 310 MIDDLE EAST & AFRICA: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 311 GCC COUNTRIES: COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2022–2029 (USD MILLION)
  • TABLE 312 GCC COUNTRIES: COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2029 (USD MILLION)
  • TABLE 313 GCC COUNTRIES: COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2022–2029 (USD MILLION)
  • TABLE 314 GCC COUNTRIES: COMPANION DIAGNOSTICS MARKET FOR CANCER, BY TYPE, 2022–2029 (USD MILLION)
  • TABLE 315 GCC COUNTRIES: COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2022–2029 (USD MILLION)
  • TABLE 316 GCC COUNTRIES: COMPANION DIAGNOSTICS MARKET, BY END USER, 2022–2029 (USD MILLION)
  • TABLE 317 COMPANION DIAGNOSTICS MARKET: STRATEGIES ADOPTED
  • TABLE 318 COMPANION DIAGNOSTICS MARKET: DEGREE OF COMPETITION
  • TABLE 319 COMPANION DIAGNOSTICS MARKET: PRODUCT FOOTPRINT
  • TABLE 320 COMPANION DIAGNOSTICS MARKET: TECHNOLOGY FOOTPRINT
  • TABLE 321 COMPANION DIAGNOSTICS MARKET: INDICATION FOOTPRINT
  • TABLE 322 COMPANION DIAGNOSTICS MARKET: REGIONAL FOOTPRINT
  • TABLE 323 COMPANION DIAGNOSTICS MARKET: DETAILED LIST OF KEY START-UPS/SMES
  • TABLE 324 COMPANION DIAGNOSTICS MARKET: COMPETITIVE BENCHMARKING OF START-UPS/SMES
  • TABLE 325 COMPANION DIAGNOSTICS MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–MARCH 2024
  • TABLE 326 COMPANION DIAGNOSTICS MARKET: DEALS, JANUARY 2021–MARCH 2024
  • TABLE 327 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
  • TABLE 328 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 329 F. HOFFMANN-LA ROCHE LTD.: PRODUCT LAUNCHES & APPROVALS
  • TABLE 330 F. HOFFMANN-LA ROCHE LTD.: DEALS
  • TABLE 331 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW
  • TABLE 332 AGILENT TECHNOLOGIES, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 333 AGILENT TECHNOLOGIES, INC.: PRODUCT APPROVALS
  • TABLE 334 AGILENT TECHNOLOGIES, INC.: DEALS
  • TABLE 335 QIAGEN: COMPANY OVERVIEW
  • TABLE 336 QIAGEN: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 337 QIAGEN: PRODUCT LAUNCHES & APPROVALS
  • TABLE 338 QIAGEN: DEALS
  • TABLE 339 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
  • TABLE 340 THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 341 THERMO FISHER SCIENTIFIC INC.: PRODUCT APPROVALS
  • TABLE 342 THERMO FISHER SCIENTIFIC INC.: DEALS
  • TABLE 343 ABBOTT: COMPANY OVERVIEW
  • TABLE 344 ABBOTT: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 345 DANAHER: COMPANY OVERVIEW
  • TABLE 346 DANAHER: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 347 GUARDANT HEALTH: COMPANY OVERVIEW
  • TABLE 348 GUARDANT HEALTH: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 349 GUARDANT HEALTH: PRODUCT LAUNCHES & APPROVALS
  • TABLE 350 GUARDANT HEALTH: DEALS
  • TABLE 351 GUARDANT HEALTH: OTHER DEVELOPMENTS
  • TABLE 352 ILLUMINA, INC.: COMPANY OVERVIEW
  • TABLE 353 ILLUMINA, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 354 ILLUMINA, INC.: PRODUCT LAUNCHES
  • TABLE 355 ILLUMINA, INC.: DEALS
  • TABLE 356 BIOMÉRIEUX: COMPANY OVERVIEW
  • TABLE 357 BIOMÉRIEUX: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 358 ICON PLC: COMPANY OVERVIEW
  • TABLE 359 ICON PLC: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 360 MYRIAD GENETICS, INC.: COMPANY OVERVIEW
  • TABLE 361 MYRIAD GENETICS, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 362 MYRIAD GENETICS, INC.: PRODUCT APPROVALS
  • TABLE 363 MYRIAD GENETICS, INC.: DEALS
  • TABLE 364 SYSMEX CORPORATION: COMPANY OVERVIEW
  • TABLE 365 SYSMEX CORPORATION: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 366 SYSMEX CORPORATION: DEALS
  • TABLE 367 SYSMEX CORPORATION: OTHER DEVELOPMENTS
  • TABLE 368 ALMAC GROUP: COMPANY OVERVIEW
  • TABLE 369 ARUP LABORATORIES: COMPANY OVERVIEW
  • TABLE 370 ABNOVA CORPORATION: COMPANY OVERVIEW
  • TABLE 371 BIOGENEX: COMPANY OVERVIEW
  • TABLE 372 INVIVOSCRIBE, INC.: COMPANY OVERVIEW
  • TABLE 373 ARCHERDX, INC.: COMPANY OVERVIEW
  • TABLE 374 Q² SOLUTIONS: COMPANY OVERVIEW
  • TABLE 375 AMOY DIAGNOSTICS CO., LTD.: COMPANY OVERVIEW
  • TABLE 376 UNIOGEN: COMPANY OVERVIEW
  • TABLE 377 ASURAGEN, INC.: COMPANY OVERVIEW
  • TABLE 378 MESO SCALE DIAGNOSTICS, LLC: COMPANY OVERVIEW
  • TABLE 379 CREATIVE BIOLABS: COMPANY OVERVIEW
  • TABLE 380 NG BIOTECH: COMPANY OVERVIEW
LIST OF FIGURES
 
  • FIGURE 1 RESEARCH DESIGN METHODOLOGY
  • FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
  • FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 4 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
  • FIGURE 5 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
  • FIGURE 6 COMPANION DIAGNOSTICS MARKET: TOP-DOWN APPROACH
  • FIGURE 7 DATA TRIANGULATION METHODOLOGY
  • FIGURE 8 COMPANION DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024 VS. 2029 (USD MILLION)
  • FIGURE 9 COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024 VS. 2029 (USD MILLION)
  • FIGURE 10 COMPANION DIAGNOSTICS MARKET, BY INDICATION, 2024 VS. 2029 (USD MILLION)
  • FIGURE 11 COMPANION DIAGNOSTICS MARKET, BY SAMPLE TYPE, 2024 VS. 2029 (USD MILLION)
  • FIGURE 12 COMPANION DIAGNOSTICS MARKET, BY END USER, 2024 VS. 2029 (USD MILLION)
  • FIGURE 13 COMPANION DIAGNOSTICS MARKET, BY REGION, 2024 VS. 2029 (USD MILLION)
  • FIGURE 14 GROWING INCIDENCE OF CANCER TO DRIVE MARKET GROWTH
  • FIGURE 15 ASSAYS, KITS, AND REAGENTS TO DOMINATE MARKET IN 2029
  • FIGURE 16 POLYMERASE CHAIN REACTION SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
  • FIGURE 17 CANCER SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
  • FIGURE 18 TISSUE SAMPLES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
  • FIGURE 19 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES SEGMENT TO LEAD MARKET IN 2029
  • FIGURE 20 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE IN COMPANION DIAGNOSTICS MARKET DURING FORECAST PERIOD
  • FIGURE 21 COMPANION DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 22 PERSONALIZED MEDICINE APPROVALS BY US FDA (2015−2022)
  • FIGURE 23 GLOBAL CANCER INCIDENCE (2008−2030)
  • FIGURE 24 PATENT ANALYSIS OF COMPANION DIAGNOSTICS SYSTEMS (JANUARY 2014–DECEMBER 2023)
  • FIGURE 25 VALUE CHAIN ANALYSIS: MAJOR VALUE-ADDED DURING MANUFACTURING & ASSEMBLY PHASES
  • FIGURE 26 COMPANION DIAGNOSTICS MARKET: SUPPLY CHAIN ANALYSIS
  • FIGURE 27 ECOSYSTEM MAP
  • FIGURE 28 REVENUE SHIFT FOR COMPANION DIAGNOSTICS MARKET
  • FIGURE 29 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF COMPANION DIAGNOSTICS PRODUCTS
  • FIGURE 30 KEY BUYING CRITERIA FOR COMPANION DIAGNOSTICS PRODUCTS
  • FIGURE 31 COMPANION DIAGNOSTICS MARKET: INVESTMENT & FUNDING SCENARIO
  • FIGURE 32 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET SNAPSHOT
  • FIGURE 33 ASIA PACIFIC: COMPANION DIAGNOSTICS MARKET SNAPSHOT
  • FIGURE 34 REVENUE ANALYSIS OF KEY PLAYERS (2019–2023)
  • FIGURE 35 MARKET SHARE ANALYSIS OF KEY PLAYERS (2023)
  • FIGURE 36 COMPANION DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
  • FIGURE 37 COMPANION DIAGNOSTICS MARKET: OVERALL FOOTPRINT
  • FIGURE 38 COMPANION DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (START-UPS/SMES), 2023
  • FIGURE 39 EV/EBITDA OF KEY VENDORS
  • FIGURE 40 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
  • FIGURE 41 PRODUCT/BRAND COMPARATIVE ANALYSIS, BY PARAMETER
  • FIGURE 42 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2023)
  • FIGURE 43 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 44 QIAGEN: COMPANY SNAPSHOT (2023)
  • FIGURE 45 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 46 ABBOTT: COMPANY SNAPSHOT (2023)
  • FIGURE 47 DANAHER: COMPANY SNAPSHOT (2023)
  • FIGURE 48 GUARDANT HEALTH: COMPANY SNAPSHOT (2023)
  • FIGURE 49 ILLUMINA, INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 50 BIOMÉRIEUX: COMPANY SNAPSHOT (2023)
  • FIGURE 51 ICON PLC: COMPANY SNAPSHOT (2023)
  • FIGURE 52 MYRIAD GENETICS, INC.: COMPANY SNAPSHOT (2023)
  • FIGURE 53 SYSMEX CORPORATION: COMPANY SNAPSHOT (2023)

Methodology

This study involved four major activities in estimating the current size of the companion diagnostics market. Exhaustive secondary research was conducted to gather information on the market, its peer markets, and its parent market. These findings, assumptions, and sizing were then validated with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. Following this, the data triangulation procedure was used to estimate the market size of segments and subsegments.

Secondary Research

Secondary research was primarily used to identify and gather information for the extensive, technical, market-oriented, and commercial study. The secondary sources referred for this research study include publications from government sources, such as the National Center for Biotechnology Information (NCBI), National Institutes of Health (NIH), World Health Organization (WHO), Food and Drug Administration (FDA), European Medicines Agency (EMA), Pharmaceutical Research and Manufacturers of America (PhRMA), Global Cancer Observatory (GLOBOCAN), Centers for Disease Control and Prevention (CDC), and European Federation of Biotechnology,. Secondary sources also included corporate and regulatory filings (such as annual reports, SEC filings, investor presentations, and financial statements); business magazines and research journals; press releases; and trade, business, and professional associations. These sources were also used to obtain key information on major players, global product revenues, market classification, and segmentation by industry trends, regional/country-level markets, market developments, and technology perspectives. Secondary data were collected and analyzed to determine the overall size of the global companion diagnostics market, and the findings were validated through primary research.

Primary Research

In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, among others, to obtain and verify critical qualitative and quantitative information and assess market prospects. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The following is a breakdown of the primary respondents:

Companion Diagnostics Market Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

The global size of the companion diagnostics market was estimated through multiple approaches. A detailed market estimation approach was used to estimate and validate the market value and other dependent submarkets. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

Companion Diagnostics Market Top Down and Bottom Up Approach

Data Triangulation

After estimating the overall market size from the market size estimation process, the total market was split into several segments. To complete the overall market engineering process and arrive at the exact statistics for all segments, the data triangulation procedure was employed; it involved studying various factors and trends from both the demand and supply sides.

Market Definition

A companion diagnostic (CDx) is an in vitro diagnostic (IVD) device that is used to make biomarker assessments to identify whether a patient with certain chronic diseases, such as cancer, infectious diseases, and cardiovascular diseases, could benefit from a particular drug provides information essential for the safe and effective use of a specific therapeutic product, particularly targeted therapies and biologics. These tests help identify patients who are most likely to benefit from a treatment, may experience adverse reactions, or require therapy selection based on biomarker or molecular profiling. The market includes assay kits, reagents, instruments, software, and laboratory testing services across technologies such as polymerase chain reaction, next-generation sequencing, immunohistochemistry, and in situ hybridization, among others.

Key Stakeholders

  • Manufacturers and Distributors of Companion Diagnostics Products
  • In Vitro Diagnostic (IVD) Companies
  • Hospital Laboratories
  • Diagnostic Laboratories
  • Diagnostics Suppliers
  • Pharmaceutical Companies
  • Research Laboratories and Academic Institutes
  • Clinical Research Organizations (CROs)
  • Research & Development (R&D) Companies
  • Academic Medical Centers/Government Research Organizations
  • Companion Diagnostics Service Providers
  • Government Associations
  • Market Research & Consulting Firms
  • Venture Capitalists & Investors

Report Objectives

  • To define, describe, segment, and forecast the global companion diagnostics market, by product & service, technology, Indication, Sample type, Drug Class Associated with CDX, Application, end user, and region
  • To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
  • To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall companion diagnostics market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To forecast the size of the market segments with respect to six regions: North America(US and Canada), Europe (Germany, France, the UK, Switzerland Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific), Latin America (Brazil, Mexico, Argentina, and the Rest of Latin America), the Middle East [GCC and the Rest of Middle East], and Africa
  • To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
  • To track and analyze company developments such as product launches & approvals, partnerships, acquisitions, agreements, collaborations, expansions, and other developments
  • To benchmark players within the market using the proprietary “Company Evaluation Matrix” framework, which analyzes market players on various parameters within the broad categories of business and product excellence strategy

Available customizations:

With the given market data, MarketsandMarkets offers customizations per the company’s specific needs. The following customization options are available for the report:

Geographical Analysis

  • Further breakdown of the Rest of Europe companion diagnostics market, by country
  • Further breakdown of the Rest of Asia Pacific companion diagnostics market, by country

Company Information

  • Detailed analysis and profiling of additional market players (up to five)

Segment Analysis

  • Cross-segment analysis

 

TABLE OF CONTENTS

METHODOLOGY

Need a Tailored Report?

Customize this report to your needs

Get 10% FREE Customization

Customize This Report
Fact checked
Cite this Research

Adjacent Markets

Request Bundle Reports

Personalize This Research

  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
Request A Free Customisation

Let Us Help You

  • What are the Known and Unknown Adjacencies Impacting the Companion Diagnostics Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
Customized Workshop Request
Forbes

Custom Market Research Services

We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements

Get 10% Free Customisation

TESTIMONIALS

Growth opportunities and latent adjacency in Companion Diagnostics Market

Alisa

Jul, 2022

What is the Companion Diagnostics Market trend by Product (Assays, Kits, Software & Services), Technology (PCR, NGS, ISH, IHC), Indication (Breast, Blood, Lung, Colorectal Cancer, Neurology Diseases), End User (Pharma Companies, CROs), Regional Analysis - Global Forecast to 2031.

Alan

Dec, 2022

Companion Diagnostics Market Report provides the global forecasts for the next five years. Companies like ResearchDx is profiled as one of the key players in this report. Included the comprehensive 360 degree competitive mapping by profiling major players of Companion Diagnostics Market. Key Questions Addressed in the Report: • Where will all these products & services take the industry in the mid to long term? • What are the growth opportunities in the Companion Diagnostics Market across major regions in the future? • Which are the key players in the market and how intense is the competition? • What are the current industry developments for companion diagnostics? We have given a comprehensive 360 degree competitive mapping by profiling major players of Companion Diagnostics Market..

DMCA.com Protection Status